EICHORPublic-registry site landscape for NCT03655535, “Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes”, a Type2 Diabetes Mellitus study sponsored by Boston Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03655535 (registry record) |
| Study title | Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes |
| Official title | Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Effect of BTI320 in Addition to Current Treatment With Metformin and/or Sulfonylureas on Glycemic Control in Subjects With Type 2 Diabetes |
| Sponsor | Boston Therapeutics |
| Condition(s) | Type2 Diabetes Mellitus |
| Phase | PHASE2 |
| Listed sites | 4 |
| Intervention(s) | BTI320 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03655535.
Eichor generates a preliminary site-risk snapshot for NCT03655535 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Type2 Diabetes Mellitus trials
← Eichor home · All tracked trials · Type2 Diabetes Mellitus studies · Weekly briefs
